Vaccine Trial Design Overhaul For HIV, Malaria, Tuberculosis Is FDA/WHO Project Goal
This article was originally published in Pharmaceutical Approvals Monthly
FDA grant will launch a collaborative agreement between the agency and the World Health Organization to create adaptive trial designs and explore new ways of tracking adverse event data.
You may also be interested in...
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.